Heparin

Generic Name
Heparin
Brand Names
Heparin Leo
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
9005-49-6
Unique Ingredient Identifier
T2410KM04A
Background

Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.

Indication

Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.

Associated Conditions
Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein
Associated Therapies
Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices

Optimized Heparin Regimen in Vascular Surgery

First Posted Date
2015-06-22
Last Posted Date
2016-01-12
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Target Recruit Count
32
Registration Number
NCT02477072
Locations
🇨🇦

Centre Hospitalier de l'Université de Montréal (CHUM-Hôtel-Dieu), Montreal, Quebec, Canada

Verapamil vs Heparin in Transradial Procedures

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-05-27
Last Posted Date
2016-10-04
Lead Sponsor
University Hospital of Ferrara
Target Recruit Count
418
Registration Number
NCT02454491
Locations
🇮🇹

University Hospital of Ferrara, Cona, Ferrara, Italy

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

First Posted Date
2015-05-19
Last Posted Date
2018-05-24
Lead Sponsor
Kaiser Permanente
Target Recruit Count
250
Registration Number
NCT02448550
Locations
🇺🇸

Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States

CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%

First Posted Date
2015-05-06
Last Posted Date
2020-10-22
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
72
Registration Number
NCT02435732

Racial Differences in Vagal Control of Glucose Homeostasis

First Posted Date
2015-02-18
Last Posted Date
2019-03-19
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
23
Registration Number
NCT02365285
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART

First Posted Date
2014-12-08
Last Posted Date
2017-05-19
Lead Sponsor
Uppsala University
Target Recruit Count
6012
Registration Number
NCT02311231
Locations
🇸🇪

Lund University, Lund, Sweden

TEG Anticoagulation Monitoring During ECMO

First Posted Date
2014-10-22
Last Posted Date
2017-07-05
Lead Sponsor
Policlinico Hospital
Target Recruit Count
42
Registration Number
NCT02271126
Locations
🇮🇹

Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Milano, Lombardy, Italy

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-08-01
Last Posted Date
2020-05-21
Lead Sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Target Recruit Count
60
Registration Number
NCT02206087
Locations
🇺🇸

Quintiles, Overland Park, Kansas, United States

Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke

Phase 2
Conditions
Interventions
First Posted Date
2014-06-09
Last Posted Date
2014-06-09
Lead Sponsor
Shiraz University of Medical Sciences
Target Recruit Count
80
Registration Number
NCT02159287
Locations
🇮🇷

Faghihi hospital, Shiraz, Fars, Iran, Islamic Republic of

🇮🇷

Nemazi hospital, Shiraz, Fars, Iran, Islamic Republic of

© Copyright 2024. All Rights Reserved by MedPath